TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States and internationally. Its products portfolio includes IMVEXXY for the treatment of moderate-to-severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause; BIJUVA to treat moderate-to-severe vasomotor symptoms due to menopause in women with a uterus; and ANNOVERA, a ring-shaped contraceptive vaginal system. The company also offers prescription prenatal vitamin products under the BocaGreenMD and vitaMedMD brand names. It has a license agreement with Mayne Pharma Group Limited. The company sells its products through wholesale distributors and retail pharmacy distributors. TherapeuticsMD, Inc. was founded in 2008 and is headquartered in Boca Raton, Florida.…
TherapeuticsMD: Q3 Earnings Snapshot
TherapeuticsMD (NASDAQ: TXMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 1 employees.
The shares were at 1.710 USD on 20 November 2026, up 34.6% over 52 weeks. Its 52-week range is 1.240 USD to 2.950 USD: the price is 42.0% below the high and 37.9% above the low.
At a market capitalisation of 19.79M USD, it trades at 171.0 times trailing earnings and 4.9 times forward earnings. The median trailing P/E of its 17 largest Drug Manufacturers - Specialty & Generic peers is 24.5, a premium of 598% for TXMD.
TherapeuticsMD reports return on equity of -2.1%, an operating margin of -37.7% and revenue up 60.6% year over year.
It holds more cash than debt, a net cash position of 6.24M USD. Its Piotroski F-score is 7 out of 9, a strong reading of its financial health.